TabletsClinical Overview
Voglibose (0.2 mg, 0.3 mg) is an oral alpha-glucosidase inhibitor. It competitively and reversibly inhibits brush-border alpha-glucosidases (sucrase, maltase, isomaltase) in the small intestinal mucosa, delaying the enzymatic hydrolysis of dietary disaccharides and complex carbohydrates into absorbable monosaccharides, specifically flattening the postprandial glucose spike without stimulating insulin. Indicated for postprandial hyperglycemia in type 2 diabetes mellitus.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally immediately with the very first bite of each main meal (breakfast, lunch, dinner) with a sip of water. Taking before or after meals significantly reduces therapeutic efficacy.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Flatulence, abdominal distension, diarrhea, borborygmi (stomach rumbling), soft stools. Rare/Severe: Severe hepatic dysfunction (rare hepatitis) and intestinal obstruction.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
In the event of acute hypoglycemia (when combined with sulfonylureas or insulin), patients MUST be treated with pure glucose (dextrose) tablets/solution; table sugar (sucrose) will NOT work because voglibose blocks sucrose digestion. Contraindicated in severe gastrointestinal disorders, inflammatory bowel disease, and intestinal obstruction.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered endocrinologist, diabetologist, or qualified physician before initiating, adjusting dosages of, or substituting any antidiabetic or hormonal medication.
Voglibose Tablets 0.3 mg
Voglibose (0.2 mg, 0.3 mg) is an oral alpha-glucosidase inhibitor. It competitively and reversibly inhibits brush-border alpha-glucosidases (sucrase, maltase, isomaltase) in the small intestinal mucosa, delaying the enzymatic hydrolysis of dietary disaccharides and complex carbohydrates into absorbable monosaccharides, specifically flattening the postprandial glucose spike without stimulating insulin. Indicated for postprandial hyperglycemia in type 2 diabetes mellitus.
Voglibose Tablets 0.2 mg
Voglibose (0.2 mg, 0.3 mg) is an oral alpha-glucosidase inhibitor. It competitively and reversibly inhibits brush-border alpha-glucosidases (sucrase, maltase, isomaltase) in the small intestinal mucosa, delaying the enzymatic hydrolysis of dietary disaccharides and complex carbohydrates into absorbable monosaccharides, specifically flattening the postprandial glucose spike without stimulating insulin. Indicated for postprandial hyperglycemia in type 2 diabetes mellitus.
Metformin Hydrochloride 500mg (Sustained Release) + Voglibose 0.2mg Tablets
Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).
Metformin Hydrochloride 500mg + Voglibose 0.3mg Tablets
Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).